Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACHE02 risk-adapted adjuvant chemotherapy after neoadjuvant mFOLFIRINOX and surgery for pancreatic adenocarcinoma
2024-519048-33-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, irinotecan, folinic acid, oxaliplatin, gemcitabine and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Rouen University Hospital. Primary endpoints: Disease-free survival and Overall survival. Planned start Nov 2025; status: authorised.
02
Drugs
fluorouracilirinotecanfolinic acidoxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-519048-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519048-33-00.